Thakur Gaurav Kr, Sharma Tusha, Krishna Latha T, Banerjee B D, Shah Harendra Kr, Guleria Kiran
Environmental and Molecular Biology Laboratory, Department of Biochemistry, University College of Medical Sciences (Delhi University) and GTB Hospital, Dilshad Garden, Delhi, India.
Department of Obst and Gynae, University College of Medical Sciences (Delhi University) and GTB Hospital, Dilshad Garden, Delhi, India.
Asian Pac J Cancer Prev. 2019 Oct 1;20(10):2923-2928. doi: 10.31557/APJCP.2019.20.10.2923.
DNA promoter methylation is widely explored epigenetic phenomena, known to effect gene expression and further perturbation in cellular homeostasis. Myriad of studies have leveraged promoter methylation and its potential as biomarker for various types of cancer. Aim of present study is to investigate promoter methylation of CDH1 and VIM gene and etiology of epithelial ovarian cancer (EOC).
Most of previous studies were qualitative; we have quantitatively assessed methylation levels in 50 EOC cases and control each through high recognition melt (HRM) technique.
At 10 % cutoff for CDH1 94% of EOC cases were found to be methylated with mean methylation of 45±13.8, whereas for control mean methylation was found to be 7.3±3.7 amongst 16 % methylation positive control samples. For VIM methylation was detected in 96% of cases with mean of 50.44±11.7 in EOC and in 12% methylation positive samples for control mean methylation was 6.24±4.3.
In short HRM based DNA methylation can serve as a robust and sensitive diagnostic method for promoter methylation detection and as a biomarker for early epithelial ovarian cancer detection.
DNA启动子甲基化是一种广泛研究的表观遗传现象，已知其会影响基因表达并进一步扰乱细胞稳态。众多研究利用启动子甲基化及其作为各种癌症生物标志物的潜力。本研究的目的是调查CDH1和VIM基因的启动子甲基化以及上皮性卵巢癌（EOC）的病因。
以往大多数研究都是定性的；我们通过高分辨率熔解（HRM）技术对50例EOC病例和对照的甲基化水平进行了定量评估。
对于CDH1，在10%的临界值下，发现94%的EOC病例甲基化，平均甲基化水平为45±13.8，而在16%甲基化阳性的对照样本中，平均甲基化水平为7.3±3.7。对于VIM，在96%的病例中检测到甲基化，EOC中的平均甲基化水平为50.44±11.7，在12%甲基化阳性的对照样本中，平均甲基化水平为6.24±4.3。
简而言之，基于HRM的DNA甲基化可作为一种强大而灵敏的诊断方法用于启动子甲基化检测，并作为早期上皮性卵巢癌检测的生物标志物。
